In this study, the loss of BAP1 resulted in an abnormal upregulation of SERPINE1 (PAI-1) and hence, SERPINE1 could be a new target for the treatment of BAP1-deficient ccRCC. Here, SERPINE1 is linked to nonpapillary renal cell carcinoma.